Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial

The Lancet Haematology - Tập 6 Số 8 - Trang e409-e418 - 2019
Brenda M. Sandmaier1,2, Brian Kornblit1,3, Barry E. Storer1, G. Olesen4, Michael B. Maris5, Amelia Langston6, Jonathan A. Gutman7, Solveig Petersen3, Thomas R. Chauncey1,2,8, Wolfgang Bethge9, Michael A. Pulsipher10, Ann E. Woolfrey1,2, Marco Mielcarek1,2, Paul J. Martin1,2, F R Appelbaum1,2, Mary E.D. Flowers1,2, David G. Maloney1,2, Rainer Storb1,2
1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
2Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA
3Department of Haematology, Rigshospitalet, Copenhagen, Denmark
4Department of Hematology and Department of Clinical Medicine, Aarhus Hospital, Aarhus, Denmark
5Colorado Blood Cancer Institute, Denver, CO, USA
6Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA
7Division of Hematology, University of Colorado School of Medicine, Aurora, CO, USA
8Marrow Transplant Unit, VA Puget Sound Health Care System, Seattle, WA, USA
9Department of Internal Medicine II – Hematology and Oncology, University Hospital of Eberhard Karls University, Tuebingen, Germany
10Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital Los Angeles, Keck School of Medicine of USC, Los Angeles, CA, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

McSweeney, 2001, Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects, Blood, 97, 3390, 10.1182/blood.V97.11.3390

Niederwieser, 2003, Blood, 101, 1620, 10.1182/blood-2002-05-1340

Storb, 2013, Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation, J Clin Oncol, 31, 1530, 10.1200/JCO.2012.45.0247

Kornblit, 2014, A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation, Haematologica, 99, 1624, 10.3324/haematol.2014.108340

Schulz, 2010, CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials, BMJ, 340, 10.1136/bmj.c332

Efron, 1971, Forcing a sequential experiment to be balanced, Biometrika, 58, 403, 10.1093/biomet/58.3.403

Przepiorka, 1995, 1994 Consensus Conference on Acute GVHD Grading, Bone Marrow Transplant, 15, 825

Sullivan, 1999, Graft-versus-host disease, 515

Gooley, 1999, Estimation of failure probabilities in the presence of competing risks: new representations of old estimators, Stat Med, 18, 695, 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O

Kahl, 2007, Relapse risk among patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning, Blood, 110, 2744, 10.1182/blood-2007-03-078592

Martin, 2004, Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation, Biol Blood Marrow Transplant, 10, 320, 10.1016/j.bbmt.2003.12.304

Maris, 2003, HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies, Blood, 102, 2021, 10.1182/blood-2003-02-0482

Marty, 2007, Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis, Blood, 110, 490, 10.1182/blood-2007-01-069294

Antin, 2003, Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation, Blood, 102, 1601, 10.1182/blood-2003-02-0489

Claxton, 2005, Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation, Br J Haematol, 130, 256, 10.1111/j.1365-2141.2005.05600.x

Cutler, 2007, Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation, Blood, 109, 3108, 10.1182/blood-2006-09-046219

Alyea, 2008, Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation, Biol Blood Marrow Transplant, 14, 920, 10.1016/j.bbmt.2008.05.024

Furlong, 2008, Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors, Biol Blood Marrow Transplant, 14, 531, 10.1016/j.bbmt.2008.02.009

Nakamura, 2012, Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis, Leuk Res, 36, 1152, 10.1016/j.leukres.2012.04.022

Kim, 2019, Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation, Ann Hematol, 98, 237, 10.1007/s00277-018-3427-1

Rodriguez, 2010, A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens, Blood, 115, 1098, 10.1182/blood-2009-03-207563

Perez-Simon, 2013, The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate, Haematologica, 98, 526, 10.3324/haematol.2012.065599

Ho, 2009, Comparison of tacrolimus and sirolimus (Tac/Sir) versus tacrolimus, sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation, Biol Blood Marrow Transplant, 15, 844, 10.1016/j.bbmt.2009.03.017

Al-Kadhimi, 2017, Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention, Bone Marrow Transplant, 52, 1304, 10.1038/bmt.2017.95

Pidala, 2012, A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation, Haematologica, 97, 1882, 10.3324/haematol.2012.067140

Pulsipher, 2014, The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial, Blood, 123, 2017, 10.1182/blood-2013-10-534297

Cutler, 2014, Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT, Blood, 124, 1372, 10.1182/blood-2014-04-567164

Armand, 2016, The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial, Br J Haematol, 173, 96, 10.1111/bjh.13931

Greco, 2016, Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation, Blood, 128, 1528, 10.1182/blood-2016-06-723205

Kasamon, 2017, Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide, Blood Adv, 1, 288, 10.1182/bloodadvances.2016002766

Thông tin
Thông tin xuất bản

The Lancet Haematology

Tập 6 Số 8

e409-e418

Thông tin tác giả